Lexaria Bioscience Corp. is a pharmaceutical company specializing in the development of novel drug delivery platforms for orally administered, lipid-soluble molecules. The company’s core technology, DehydraTECH®, is designed to enhance the absorption, onset and bioavailability of compounds such as cannabinoids, nicotine and certain pharmaceutical actives. By embedding these compounds into food and beverage products or nutraceuticals, Lexaria aims to offer a more efficient alternative to traditional delivery methods.
Established in 2012 and headquartered in Kelowna, British Columbia, Lexaria has conducted preclinical and clinical studies to validate its DehydraTECH® platform. The technology has been applied across multiple product categories, including prescription drug candidates, over-the-counter consumer goods and wellness supplements. Lexaria pursues collaboration and licensing agreements with industry partners to integrate its delivery system into a range of formulations.
In its pharmaceutical pipeline, Lexaria has advanced a variety of cannabinoid-based drug candidates targeting cardiovascular health, pain management and inflammation. The company also explores applications for nicotine reduction products and the enhanced delivery of vitamins and antiviral agents. Through ongoing research partnerships with academic institutions and contract research organizations, Lexaria continues to expand the evidence base supporting DehydraTECH®’s performance.
Lexaria’s leadership team is led by President and Chief Executive Officer Mr. Greg Gzerowicz, alongside founder and Chairman Mr. Chris Bunka. As a publicly traded entity on the NASDAQ under the symbol LEXXW, the company operates primarily in North America but actively pursues regulatory approvals and commercial collaborations in Europe, Latin America and the Asia-Pacific region. Lexaria remains focused on unlocking the full potential of lipid-soluble therapeutics through innovative drug delivery solutions.
AI Generated. May Contain Errors.
